Clinical Trial Update: Phase 3 Imaging and Safety Study of AI-700 in Patients With Suspected Coronary Artery Disease Undergoing SPECT Imaging [Phase 3]

View source ↗

Summary

A Phase 3 imaging and safety trial of the agent AI-700 in patients with suspected coronary artery disease undergoing SPECT imaging has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• AI-700

Snippet

Sponsor: Acusphere | Conditions: Coronary Artery Disease | Phase 3 | Status: COMPLETED